Table 1.
Baseline clinical characteristics of cancer patients who received FMT (n = 19)
| Characteristic | Value |
|---|---|
| Age, mean (SD), y | 66.5 (13.6) |
| Male sex, no. (%) | 8 (42%) |
| Race, no. (%) | |
| White | 16 (84%) |
| Other | 3 (16%) |
| Concomitant comorbidities, no. (%)a | 16 (84%) |
| ECOG status, no. (%) (n = 15) | |
| 0-2 | 14 (70%) |
| 3 | 1 (15%) |
| Smoking, no. (%) | 10 (50%) |
| Concurrent immune checkpoint inhibitor-related colitis, no. (%) | 3 (15%) |
| Cancer type, no. (%) | |
| Hematologic malignancy | 7 (37%) |
| Solid tumor | 12 (63%) |
| Cancer stage, no. (%) (n = 10) | |
| II | 1 (5%) |
| III | 2 (11%) |
| IV | 7 (37%) |
| Cancer status at time of FMT, no. (%) | |
| Remission | 4 (21%) |
| Stable disease | 9 (47%) |
| Progression | 6 (32%) |
| Immunosuppressant use 3 months before FMT, no. (%) | 7 (37%) |
| Cancer treatment 6 months before FMT, no. (%) | 16 (84%) |
| Overall mortality | 4 (21%) |
ECOG, Eastern Cooperative Oncology Group; SD, standard deviation; FMT, fecal microbiota transplantation.
a Comorbidities included diabetes mellitus, hypertension, cirrhosis, autoimmune disorder, coronary artery disease, chronic kidney disease, HIV, gastrointestinal graft versus host disease.